catalyst · primary record
Brelovitug (BJT-778) + Bulevirtide
Phase readout · 2027-08-31 · Chronic Hepatitis D
| Company | Mirum Pharmaceuticals, Inc. |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P2/P3 primary completion · NCT07454837 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T10:37:48.451Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Mirum Pharmaceuticals, Inc.:Brelovitug (BJT-778) + Bulevirtide:2027-08-31:P2/P3 primary completion · NCT07454837
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.